Third Harmonic Bio Company Profile - aVenture Research
Third Harmonic Bio
A clinical-stage biopharmaceutical company, Third Harmonic Bio developed a highly selective oral KIT inhibitor for dermal, respiratory, gastrointestinal inflammatory diseases.
Third Harmonic Bio was a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases, with oral KIT inhibition for inflammatory disease as its therapeutic category.
By inhibiting KIT, the company believed it could provide broad symptomatic relief across disorders including chronic spontaneous urticaria and severe asthma. The existing management paradigm used a nonsedating H1 antihistamine, with omalizumab added for patients who did not achieve satisfactory control, while shutting off the mast cell could yield more effective or at least alternative therapies for urticaria.